Cyclic peptide for treating cancer

A method of treating cancer comprising administering to a subject having the cancer with a therapeutically effective amount of a cyclic peptide selected from the group consisting of:

• the amino acid sequence consisting of SEQ ID NO:
• 3 (Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4), wherein X5 is glycine, alanine, leucine, isoleucine, or valine, X1 is valine, X2 is leucine, and X3 and X4 are each independently valine, leucine, isoleucine, or alanine;
• the amino acid sequence consisting of SEQ ID NO:
• 4 (X10-Gly-Glu-Val-Leu-X11-Met-Glu-Asp-Asp-Leu-Val), wherein X10 is lysine or arginine, and X11 is glutamine;
• the amino acid sequence consisting of SEQ ID NO:
• 5 (Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val), wherein X6 and X7 are each independently glutamic acid, and X8 and X9 are each independently glutamic acid or aspartic acid;
• the amino acid sequence consisting of SEQ ID NO:
• 9 (Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4), wherein X5 is glycine, alanine, leucine, isoleucine, or valine, X1 is valine, X2 is leucine, X12 is methionine or norleucine, and X3 and X4 are each independently valine, leucine, isoleucine, or alanine;
• and
• the amino acid sequence consisting of SEQ ID NO:
• 10 (X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4), wherein X10 is lysine or arginine, X5 is glycine, alanine, leucine, isoleucine, or valine, X6 is glutamic acid, X9 is glutamic acid or aspartic acid, NS X3 and X4 are each independently valine, leucine, isoleucine, or alanine,
• wherein the cyclic peptide is circularized by forming an amide bond between the N-terminal amino acid and the C-terminal amino acid, and
• wherein the cancer is selected from lung carcinoma, liver carcinoma, testicular cancer, pancreatic carcinoma, brain glioma, pancreatic ductal adenocarcinoma, colorectal carcinoma, osteosarcoma, cervical cancer, or breast cancer.